Login to Your Account

Analyst: May Be Worth the Wait

Amicus Falls on Fabry Delay, Seeks 'More Robust Dataset'

By Jennifer Boggs
Managing Editor

Tuesday, June 18, 2013
News of at least a three quarter delay in seeking regulatory approval for Fabry disease candidate migalastat unsurprisingly sent shares of Amicus Therapeutics Inc. falling 24 percent in Monday morning trading, but reports of the firm's recent meeting with the FDA left room for optimism for the Glaxosmithkline plc-partnered molecular chaperone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription